 |
Glucosamine is an amino sugar that is an important precursor in the biochemical synthesis of glycosylated proteins and lipids. Glucosamine is commonly used as a treatment for osteoarthritis, although its acceptance as a medical therapy varies. |
¡Ø
Table. Physico-chemical properties of D-GlucosamineHCl |
Product Name |
D-GlucosamineHCl |
CAS
No. |
66-84-2 |
Structural formula |
 |
Molecular formula |
|
FW |
215.7 |
Solubility |
Soluble in water (100 g/L, SigmaAldrich) |
pH |
3.5~5.0 |
Isoelectric point |
- |
Taste |
Slightly sweet tasting |
Odor |
None |
Appearance |
White crystalline powder |
|
 |
Treatment with oral glucosamine is commonly used for the treatment of osteoarthritis.
Since glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, supplemental glucosamine may help to rebuild cartilage and treat arthritis. However, there is little evidence that any clinical effect of glucosamine works this way.
Its use as a therapy for osteoarthritis appears safe but there is conflicting evidence as to its effectiveness.
|
 |
Treatment with oral glucosamine is commonly used for the treatment of osteoarthritis.
Since glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, supplemental glucosamine may help to rebuild cartilage and treat arthritis. However, there is little evidence that any clinical effect of glucosamine works this way.
Its use as a therapy for osteoarthritis appears safe but there is conflicting evidence as to its effectiveness. |
 |
Glucosamine has been studied as a medical therapy since at least the early 1980s. The clinical studies have consistently reported that glucosamine appears safe. Although no allergic reactions have been reported, glucosamine is usually derived from shellfish, so individuals with an allergy to shellfish may wish to avoid glucosamine. Alternative sources using fungal fermentation of corn are available. Another concern has been that the extra glucosamine could contribute to diabetes by interfering with the normal regulation of the hexosamine biosynthesis pathway, but several investigations have found no evidence that this occurs. The U.S. National Institutes of Health is currently conducting a study of supplemental glucosamine in obese patients, since this population may be particularly sensitive to any effects of glucosamine on insulin resistance. Finally, in the United States, glucosamine is sold as a dietary supplement, so safety and formulation is solely the responsibility of the manufacturer. |
 |